EP2956132A4 - Modulation of asymmetric proliferation - Google Patents

Modulation of asymmetric proliferation Download PDF

Info

Publication number
EP2956132A4
EP2956132A4 EP13839774.0A EP13839774A EP2956132A4 EP 2956132 A4 EP2956132 A4 EP 2956132A4 EP 13839774 A EP13839774 A EP 13839774A EP 2956132 A4 EP2956132 A4 EP 2956132A4
Authority
EP
European Patent Office
Prior art keywords
modulation
proliferation
asymmetric
asymmetric proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13839774.0A
Other languages
German (de)
French (fr)
Other versions
EP2956132A1 (en
Inventor
Sridhar Ramaswamy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Ramaswamy Sridhar
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramaswamy Sridhar, General Hospital Corp filed Critical Ramaswamy Sridhar
Publication of EP2956132A1 publication Critical patent/EP2956132A1/en
Publication of EP2956132A4 publication Critical patent/EP2956132A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP13839774.0A 2012-09-21 2013-09-20 Modulation of asymmetric proliferation Withdrawn EP2956132A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261704033P 2012-09-21 2012-09-21
PCT/US2013/060842 WO2014047398A1 (en) 2012-09-21 2013-09-20 Modulation of asymmetric proliferation

Publications (2)

Publication Number Publication Date
EP2956132A1 EP2956132A1 (en) 2015-12-23
EP2956132A4 true EP2956132A4 (en) 2017-03-01

Family

ID=50341954

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13839774.0A Withdrawn EP2956132A4 (en) 2012-09-21 2013-09-20 Modulation of asymmetric proliferation

Country Status (3)

Country Link
EP (1) EP2956132A4 (en)
GB (1) GB2528604A (en)
WO (1) WO2014047398A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112257A1 (en) * 2015-01-09 2016-07-14 Sridhar Ramaswamy Modulation of asymmetric proliferation
RU2665965C1 (en) * 2017-12-12 2018-09-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации" (ФГБУ "НМИЦ радиологии" Минздрава России) Method for screening malignant neoplasms in humans

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015140A1 (en) * 2007-01-11 2010-01-21 Critical Outcome Technologies Inc. Inhibitor Compounds and Cancer Treatment Methods
WO2012177925A1 (en) * 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015140A1 (en) * 2007-01-11 2010-01-21 Critical Outcome Technologies Inc. Inhibitor Compounds and Cancer Treatment Methods
WO2012177925A1 (en) * 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
H. HIRAI ET AL: "MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo", MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 7, 1 July 2010 (2010-07-01), pages 1956 - 1967, XP055074270, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-1012 *
QINGSONG LIU ET AL: "Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1 H )-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 19, 14 October 2010 (2010-10-14), pages 7146 - 7155, XP055099992, ISSN: 0022-2623, DOI: 10.1021/jm101144f *
See also references of WO2014047398A1 *
SINI PATRIZIA ET AL: "Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.", AUTOPHAGY MAY 2010, vol. 6, no. 4, May 2010 (2010-05-01), pages 553 - 554, XP002762085, ISSN: 1554-8635 *

Also Published As

Publication number Publication date
WO2014047398A1 (en) 2014-03-27
EP2956132A1 (en) 2015-12-23
GB201518978D0 (en) 2015-12-09
GB2528604A (en) 2016-01-27

Similar Documents

Publication Publication Date Title
IL237970A0 (en) Modulation of ire1
PT3461895T (en) Modulation of ube3a-ats expression
EP2776564A4 (en) Modulation of tmprss6 expression
EP2956132A4 (en) Modulation of asymmetric proliferation
AU2013903557A0 (en) Modulation of gene expression
AU2012902655A0 (en) New way of Implementing Software
AU2012905650A0 (en) Applicator
AU2012901761A0 (en) Applicator
AU2012901681A0 (en) Applicator
AU2012902816A0 (en) Is ts
AU2012901320A0 (en) Microwave mulesing of sheep
AU2012904621A0 (en) Detachable lamp
AU2012901839A0 (en) Texta idea
AU2012902955A0 (en) Carrier
AU2012900254A0 (en) Bioreactor
AU2012901175A0 (en) tri-guard
AU2012901408A0 (en) Skydorm
AU2012901403A0 (en) Rigitape
AU2012901401A0 (en) Cardsndice
AU2012901209A0 (en) Swimaid
AU2012901217A0 (en) TTWWaterFilter
AU2012901207A0 (en) Freakard
AU2012900939A0 (en) I-mbrella
AU2012900942A0 (en) Fin2012
AU2012900820A0 (en) Noteslap

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5025 20060101ALI20160929BHEP

Ipc: A61K 31/352 20060101AFI20160929BHEP

Ipc: A61K 31/437 20060101ALI20160929BHEP

Ipc: A61P 35/00 20060101ALI20160929BHEP

Ipc: A61K 31/495 20060101ALI20160929BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/352 20060101AFI20170124BHEP

Ipc: A61K 31/495 20060101ALI20170124BHEP

Ipc: A61K 31/5025 20060101ALI20170124BHEP

Ipc: A61K 31/437 20060101ALI20170124BHEP

Ipc: A61P 35/00 20060101ALI20170124BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GENERAL HOSPITAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170829